Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

Next Previous
Trial Profile

A Phase I/II Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Copanlisib (Primary) ; Nivolumab (Primary)
  • Indications Colorectal cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 02 Jan 2024 Planned End Date changed from 1 Dec 2023 to 30 Jun 2025.
  • 13 Jun 2023 Number of treatment arms have been increased from 2 to 3 by the addition of Experimental: Phase II/Arm B -P13K wild type /Copanlisib and Nivolumab arm. The previously existing Phase 2 arms has been labelled as Arm A.
  • 01 Mar 2023 Planned End Date changed from 1 Jun 2023 to 1 Dec 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top